Pharmacological properties of hirudin and its derivatives: Potential clinical advantages over heparin

Drugs and Aging

Volumn 8, Issue 3, 1996, Pages 171-182

  Monreal, Manuel ^a   Costa, Joan ^a   Salva, Pau ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; DESULFATOHIRUDIN; HIRUDIN; LEPIRUDIN; THROMBIN INHIBITOR;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEECH; MAJOR CLINICAL STUDY; META ANALYSIS; MOLECULAR WEIGHT; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

EID: 0029879858     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608030-00003     Document Type: Review

References (52)

1. Markwardt F. Past, present and future of hirudin. Haemostasis 1991; 21 Suppl. 1: 11-26
2. Markwardt F, Schäfer G, Töpfer H, et al. Die isolierung des hirudins aus medizinischen blutegeln [in German]. Pharmazie 1967; 22: 239-41
3. Bagdy D, Barabas E, Graf L. Large-scale preparation of hirudin. Thromb Res 1973; 2: 229-38
4. Baskova IP, Cherkesova DU, Mosolov VV. Hirudin from leech heads and whole leeches and 'pseudo-hirudin' from leech bodies. Thromb Res 1983; 30: 459-67
5. Wallis RB. Hirudins and the role of thrombin: lessons from leeches. Trends Pharmacol Sci 1988; 9: 425-7
6. Meyer BH, Luus HG, Müller FO, et al. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990; 78: 268-70
7. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101
8. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141-52
9. Markwardt F, editor. Hirudin. Semin Thromb Haemost 1991; 17: 79-159
10. Editorial. Hirudins: return of the leech? Lancet 1992; 340: 579-80
11. Bar-Shavit R, Eldora A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989; 84: 1096-104
12. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535-40
13. Marckwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Haemost 1989; 15: 269-82
14. Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharm 1993; 22: 364-72
15. Verstraete M, Nurmohamed M, Kienast J, et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993; 22: 1080-8
16. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36
17. ™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63
18. Becker RC, Ansell J. Antithrombotic therapy. An abbreviated reference for clinicians. Arch Intern Med 1995; 155: 149-61
19. Eriksson BI, Kälebo P, Ekman S, et al. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72 (2): 227-31
20. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90: 2385-9
21. ™Revasc-Ciba), in patients undergoing total hip replacement [abstract]. Thromb Haemost 1995; 73: 1108
22. ™Revasc-Ciba), is the most effective and safe prophylaxis of thromboembolic complications in patients undergoing total hip replacement [abstract]. Thromb Haemost 1995; 73: 1093
23. Doyle DJ, Turpie AGG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-5
24. Monreal M, Lafoz E, Ruiz J, et al. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: a prospective study. Eur J Vasc Surg 1994; 8: 584-9
25. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82
26. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 1993; 70 (3): 386-8
27. Schiele F, Vuillemenot A, Kramarz PH, et al. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71 (5): 558-62
28. ™ in patients with calf vein thrombosis. Thromb Haemost 1994; 72 (4): 523-5
29. Moia M, Schiele F, Walker M, et al. Treatment of acute deep vein thrombosis (DVT) by subcutaneous r-hirudin (HBW 023): a multicentre study [abstract]. Thromb Haemost 1995; 73: 1456
30. Théroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5
31. Sharma GVRK, Lapsley D, Vita JA, et al. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993; 72: 1357-60
32. Lidón RM, Théroux P, Juneau M, et al. Initial experience with a direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 1993; 88 (Pt 1): 1495-501
33. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994; 89: 1557-66
34. Schreiber TL, Rizik D, White C, et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86: 1407-14
35. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11
36. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-71
37. Topol EJ, Bonan R, Jewitt D, et al. Effect of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-9
38. van den Bos AA, Deckers JW, Heyndrickx GR, et al. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88 (Pt 1): 2058-66
39. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-63
40. Bittl JA, Strony J, Brinker JA, et al. Treatment with Bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9
41. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
42. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-27
43. Harker LA. Pathogenesis of thrombosis. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, editors. Hematology. 4th ed. New York: McGraw-Hill, 1990: 1559-69
44. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinanl desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993-1003
45. Lee LV, for the TIMI 6 investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol 1995; 75: 7-13
46. Antman EM, for the TIMI 9 investigators. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9 Trial. Circulation 1994; 90: 1624-30
47. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ila Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7
48. Neuhaus KL, Essen RV, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study. A study of the Arbeitsgemeinschaft leitender kardiologischer krankenhausärzte (ALKK). Circulation 1994; 90: 1638-42
49. Lidón RM, Théroux P, Lespérance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567-72
50. Théroux P, Pérez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-9
51. Tripodi A, Chantarangkul V, Arbini AA, et al. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70: 286-8
52. Monreal M, Monreal L, Ruiz de Gopegui R, et al. Effects of two different doses of hirudin on aPTT, determined with eight different reagents. Thromb Haemost 1995; 73: 219-22